Across TCGA pan-cancer cohorts, MTOR mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MTOR data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MTOR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTOR expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where MTOR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.610	0.835	<.001	74	view →
HNSC	DFS	Median	III,IV	0.488	0.710	.011	17	view →
CCRCC	OS	Median	II,III,IV	0.884	0.635	.016	2	view →
LUAD	OS	Median	II,III,IV	0.963	0.899	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MTOR tumor-vs-normal RNA expression · all MTOR data types